In a recent study using patient-derived xenograft models of triple-negative breast cancer, lartesertib in combination with the ATR inhibitor gartisertib led to a substantially improved tumor control rate compared with single-agent gartisertib (42% vs. 27%; 17). This evidence concerns the gene ATR and neoplasm.